5-methyl-4-[1]naphthyl-thiazol-2-ylamine | 107411-05-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-methyl-4-[1]naphthyl-thiazol-2-ylamine
• 英文别名: 2-Thiazolamine, 5-methyl-4-(1-naphthalenyl)-；5-methyl-4-naphthalen-1-yl-1,3-thiazol-2-amine
• CAS: 107411-05-2
• 化学式: C₁₄H₁₂N₂S
• mdl: MFCD20171325
• 分子量: 240.329
• InChiKey: WOXJGUKYQNONEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-bromo-1-(1-naphthyl)-1-propanone 、 硫脲 在 甲醇 、 盐酸 、 乙醚 、 二氯甲烷 、 氯仿 、 水 、 Sodium sulfate-III 作用下， 以 甲苯 为溶剂， 反应 2.0h， 以The title compound (1) (4.45 g, m.p. 194-195° C.) was obtained的产率得到5-methyl-4-[1]naphthyl-thiazol-2-ylamine
  参考文献：
  名称：

  5-Ht2b receptor antagonists

  摘要：

  本发明涉及公式（I）的化合物：其中R1选自H，及可选取的取代C1-6烷基，C3-7环烷基，C3-7环烷基-C1-4烷基和苯基-C1-4烷基；R2和R3是：（i）独立选自H，R，R'，SO2R，C（═O）R，（CH2）nNR5R6，其中n为1至4，R5和R6独立选自H和R，其中R为可选取的取代C1-4烷基，R'为可选取的取代苯基-C1-4烷基，或（ii）与它们所连接的氮原子一起形成可选取的取代C5-7杂环基；R4为可选取的取代C9-14芳基基团；其用途为制成药物，特别是用于治疗通过5-HT2B受体拮抗缓解的疾病。

  公开号：

  US20050154031A1

文献信息

• 5-HT2B RECEPTOR ANTAGONISTS
  申请人：Pharmagene Laboratories Ltd

  公开号：EP1474141A1

  公开（公告）日：2004-11-10
• [EN] 5-HT2B RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR 5-HT2B
  申请人：PHARMAGENE LAB LTD

  公开号：WO2003068227A1

  公开（公告）日：2003-08-21

  The present invention concerns compounds of formula (I): wherein R1 is selected from the group consisting of H, and optionally substituted C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-4 alkyl, and phenyl-C 1-4 alkyl;R2 and R3 are either: (i) independently selected from H, R, R', SO2R, C(=O)R, (CH2)nNR5R6, where n is from 1 to 4 and R5 and R6 are independently selected from H and R, where R is optionally substituted C 1-4 alkyl group, and R' is an optionally substituted phenyl- C 1-4 alkyl group, or (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C 5-7 heterocyclic group; R4 is an optionally substituted C 9-14 aryl group; their use as pharmaceuticals, in particular for treating conditions alleviated by antagonism of a 5-HT 2B receptor.
• 5-Ht2b receptor antagonists
  申请人：Oxford William Alexander

  公开号：US20050154031A1

  公开（公告）日：2005-07-14

  The present invention concerns compounds of formula (I): wherein R 1 is selected from the group consisting of H, and optionally substituted C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-4 alkyl, and phenyl-C 1-4 alkyl; R 2 and R 3 are either: (i) independently selected from H, R, R′, SO 2 R, C(═O)R, (CH 2 ) n NR 5 R 6 , where n is from 1 to 4 and R 5 and R 6 are independently selected from H and R, where R is optionally substituted C 1-4 alkyl group, and R′ is an optionally substituted phenyl-C 1-4 alkyl group, or (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C 5-7 heterocyclic group; R 4 is an optionally substituted C 9-14 aryl group; their use as pharmaceuticals, in particular for treating conditions alleviated by antagonism of a 5-HT 2B receptor.

  本发明涉及公式（I）的化合物：其中R1选自H，及可选取的取代C1-6烷基，C3-7环烷基，C3-7环烷基-C1-4烷基和苯基-C1-4烷基；R2和R3是：（i）独立选自H，R，R'，SO2R，C（═O）R，（CH2）nNR5R6，其中n为1至4，R5和R6独立选自H和R，其中R为可选取的取代C1-4烷基，R'为可选取的取代苯基-C1-4烷基，或（ii）与它们所连接的氮原子一起形成可选取的取代C5-7杂环基；R4为可选取的取代C9-14芳基基团；其用途为制成药物，特别是用于治疗通过5-HT2B受体拮抗缓解的疾病。

表征谱图